ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Cycloastragenol overcomes trastuzumab resistance in HER2-positive breast cancer by regulating cell cycle and epithelial-mesenchymal transition through EZH2/PTEN/AKT pathway.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The resistance of human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) patients to trastuzumab (Tmab) severely restricts its efficacy. As a natural metabolite with antitumor activity, whether cycloastragenol (CAG) can overcome Tmab resistance and its related mechanism are not clear. This study aims to verify if CAG reverses Tmab resistance in HER2-positive breast cancer cells, clarify its regulatory effects on resistant cell behaviors, and explore the role of the EZH2/PTEN/AKT axis. The study design is combined in vivo and in vitro study. The BT474-TR cells were constructed, and HER2 expression was detected by Western blot and immunofluorescence. Cell Counting Kit-8 assay served to screen the optimal CAG concentration and Tmab dosage. Cell proliferation, migration, and invasion capabilities were evaluated via CFSE staining, colony formation assay, and Transwell and scratch assays. Flow cytometry was employed to examine apoptosis and cell cycle arrest. A xenograft tumor model was established in nude mice. Pathological changes were observed via HE staining, apoptosis was detected using TUNEL staining, microvascular density and VEGF levels were assessed by immunohistochemistry, and protein expression was validated by Western blot. Tmab reduced BT474-TS cell viability and downregulated HER2, while exhibiting minimal effects on HER2-high expression BT474-TR and JIMT-1 cells. CAG treatment enhanced the efficacy of Tmab against drug-resistant cells, reducing cell viability and proliferation, promoting apoptosis, and inducing G0/G1 phase cycle arrest. CAG suppressed migration and invasion capabilities while reversing the EMT phenotype. Additionally, CAG downregulated EZH2 and p-AKT while upregulating PTEN; overexpression EZH2 diminished CAG's antitumor activity. Following CAG combined with Tmab treatment, tumor volume and weight in nude mice were smaller, and tumor tissue exhibited increased pathological damage, elevated apoptotic cells, and reduced microvascular density and VEGF levels. CAG modulates the cell cycle and EMT through the EZH2/PTEN/AKT pathway, effectively overcoming Tmab resistance in HER2-positive BC cells. Clinical trial number: Not applicable.
Indexed as
Identifiers
42507167What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.